Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study
Eur Urol. 2026 Jan;89(1):71-79.
https://pubmed.ncbi.nlm.nih.gov/41130825/
An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC)
Radiother Oncol. 2026 Jan;214:111227.
https://pubmed.ncbi.nlm.nih.gov/41138857/
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial
Radiother Oncol. 2026 Jan;214:111202.
https://pubmed.ncbi.nlm.nih.gov/41173355/
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Lancet Oncol. 2026 Jan;27(1):45-56.
https://pubmed.ncbi.nlm.nih.gov/41449147/
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
Lancet Oncol. 2026 Jan;27(1):23-35.
https://pubmed.ncbi.nlm.nih.gov/41449145/
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-Risk Patients With Breast Cancer (HYPART): Acute Toxicity Results
Int J Radiat Oncol Biol Phys. 2026 Jan 1;124(1):133-146.
https://pubmed.ncbi.nlm.nih.gov/40780546/
Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial
Int J Radiat Oncol Biol Phys. 2026 Jan 1;124(1):109-121.
https://pubmed.ncbi.nlm.nih.gov/40752655/
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial
Lancet. 2026 Jan 24;407(10526):363-374.
https://pubmed.ncbi.nlm.nih.gov/41448222/
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Lancet. 2026 Jan 10;407(10524):174-184.
https://pubmed.ncbi.nlm.nih.gov/41391462/
PDF
Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC
Radiother Oncol. 2026 Feb;215:111323.
https://pubmed.ncbi.nlm.nih.gov/41389860/
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
J Clin Oncol. 2026 Feb;44(4):274-285.
https://pubmed.ncbi.nlm.nih.gov/41397208/
Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study
Int J Radiat Oncol Biol Phys. 2026 Feb 1;124(2):278-293.
https://pubmed.ncbi.nlm.nih.gov/41033612/
O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial
Lancet Oncol. 2026 Feb;27(2):169-180.
https://pubmed.ncbi.nlm.nih.gov/41429128/
Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial
Int J Radiat Oncol Biol Phys. 2026 Feb 1;124(2):349-358.
https://pubmed.ncbi.nlm.nih.gov/40876576/
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial
Eur Urol. 2026 Mar;89(3):199-203.
https://pubmed.ncbi.nlm.nih.gov/41494929/
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial
J Clin Oncol. 2026 Mar;44(7):534-539.
https://pubmed.ncbi.nlm.nih.gov/41512219/
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
J Clin Oncol. 2026 Mar;44(7):586-597.
https://pubmed.ncbi.nlm.nih.gov/41337691/
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005
J Clin Oncol. 2026 Mar 10;44(8):630-640.
https://pubmed.ncbi.nlm.nih.gov/41529214/
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
Lancet Oncol. 2026 Mar;27(3):293-301.
https://pubmed.ncbi.nlm.nih.gov/41655576/
Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren's Disease: Three-Year Secondary Analysis Data From the Prevention Group of the International Dupuytren's Evaluation of Preventative or Adjuvant Radiation Therapy (DEPART) Randomized Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 1;124(3):604-613.
https://pubmed.ncbi.nlm.nih.gov/41027544/
Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 15;124(4):928-936
https://pubmed.ncbi.nlm.nih.gov/41106690/
Parotid-Sparing Versus Conventional Whole Brain Radiation Therapy: A Multi-Institutional Randomized Clinical Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 15;124(4):1024-1032.
https://pubmed.ncbi.nlm.nih.gov/41161645/
Effectiveness of Low-Cost Polyurethane Film in Reducing Dermatitis Severity in Breast Cancer Patients With Higher Fitzpatrick Skin Types Undergoing Hypofractionated Irradiation With Simultaneous Integrated Boost: An Intrapatient Randomized Controlled Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 15;124(4):952-960.
https://pubmed.ncbi.nlm.nih.gov/41187861/
Simultaneous Integrated Dose Reduction Radiation Therapy Versus Conventional Fractionated Radiation Therapy With Chemotherapy for Limited-Stage Small Cell Lung Cancer in the Modern Treatment Era: A Phase 3, Randomized Clinical Trial (SDR-RT trial)
Int J Radiat Oncol Biol Phys. 2026 Mar 1;124(3):692-701.
https://pubmed.ncbi.nlm.nih.gov/41101556/
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial
Lancet. 2026 Mar 7;407(10532):976-987.
https://pubmed.ncbi.nlm.nih.gov/41794436/
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial
Lancet. 2026 Mar 28;407(10535):1259-1275.
https://pubmed.ncbi.nlm.nih.gov/41875914/
PDF
